PLUS: MGM settles breach suits; AWS doesn't trust you with security defaults; A new .NET backdoor; and more Infosec in brief ...

You may have heard in the news that the U.S. Food and Drug Administration will no longer allow the use of FD&C Red Dye No. 3 ...

If you are pregnant or nursing, talk with your health care professional about whether to enroll in pregnancy safety or ...

The FDA has approved Journavx, an oral medication for treating pain that doesn't target the brain like addictive opioids.

Suzetrigine, to be sold under the brand name Journavx, is the first new type of pain medicine approved by the FDA in more ...

The FDA has approved Journavx, a pain medication, offering a safer alternative to opioids. Learn about its benefits and side ...

The US Food and Drug Administration has approved a new, nonopioid pain medication for treating moderate to severe acute pain.

The Cybersecurity and Infrastructure Security Agency and Food and Drug Administration Jan. 30 released notices warning of ...

The medication offers relatively modest pain relief, underscoring the challenges of finding new ways to manage pain.

The drug represents a new pathway to treating people with pain due to surgeries or traumatic injuries, avoiding the addictive risks of opioids.

The FDA on Thursday approved a new class of pain medication that provides an alternative to opioids. It will be sold under ...

The U.S. Food and Drug Administration has approved Journavx (suzetrigine) 50 milligram oral tablets, marking the introduction ...